Curaleaf Holdings (CURLF) Shares Outstanding (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Shares Outstanding (Entity) of $775.4 million for Q1 2026, up 4.1% year-over-year from $744.9 million in Q1 2025, and up 1.75% quarter-over-quarter from $762.1 million in Q4 2025.
Curaleaf Holdings (CURLF) Shares Outstanding (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $775.4 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 4.1% year-over-year to $775.4 million; the TTM figure through Mar 2026 stood at $775.4 million (up 4.1% YoY), while the FY2025 annual figure was $762.1 million, up 2.87% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $775.4 million, up from $762.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $775.4 million in Q1 2026, with the low at $708.9 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $736.1 million (2024), against an average of $734.6 million.
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Entity) rose 1.18% in 2022, then rose 4.1% in 2026.
- Curaleaf Holdings' Shares Outstanding (Entity) stood at $711.2 million in 2022, then grew by 1.82% to $724.1 million in 2023, then grew by 2.31% to $740.8 million in 2024, then rose by 2.87% to $762.1 million in 2025, then gained by 1.75% to $775.4 million in 2026.
- Business Quant data shows CURLF's Shares Outstanding (Entity) at $775.4 million in Q1 2026, $762.1 million in Q4 2025, and $764.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 832.44 Mn |
| 10 | Curaleaf Holdings | 2.51 Bn | 2.42 Bn | 169.91 Mn | 263.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 263.07 Mn |
| Mar 31, 2026 | 775.43 Mn |
| Dec 31, 2025 | 762.09 Mn |
| Sep 30, 2025 | 764.83 Mn |
| Jun 30, 2025 | 757.27 Mn |
| Mar 31, 2025 | 744.90 Mn |
| Dec 31, 2024 | 740.83 Mn |
| Sep 30, 2024 | 739.83 Mn |
| Jun 30, 2024 | 740.79 Mn |
| Mar 31, 2024 | 736.15 Mn |
| Dec 31, 2023 | 724.12 Mn |
| Sep 30, 2023 | 725.32 Mn |
| Jun 30, 2023 | 719.27 Mn |
| Mar 31, 2023 | 718.12 Mn |
| Dec 31, 2022 | 711.16 Mn |
| Sep 30, 2022 | 709.64 Mn |
| Jun 30, 2022 | 709.97 Mn |
| Mar 31, 2022 | 708.90 Mn |
| Dec 31, 2021 | 698.76 Mn |
| Sep 30, 2021 | 695.83 Mn |